Objective
Mantle cell lymphoma (MCL) is a distinct, clinically very aggressive subentity of malignant lymphoma with a median survival of 3 years. However, a small subset of patients represents long-term survivors. So far, the discriminative power of different prognostic parameters has been limited. Thus, a better understanding of the underlying molecular mechanisms is eagerly warranted. In the last few years, European-wide MCL networks of clinicians (European MCL Intergroup Working Party), pathologists (European MCL Pathology Panel) and basic researchers (European MCL Research Network) have been established to investigate the clinical as well as molecular aspects of malignant transformation and progression in MCL. Especially, strict diagnostic histomorphological criteria have been defined; in a prospective randomized study, an intensive consolidation with high dose radiochemotherapy and subsequent autologous stem cell transplantation resulted in superior progression-free and overall survival rates; and most interestingly, proliferation indices have been identified as the most important prognostic factors in MCL superior to clinical parameters (IPI). Based on these extensive prerequisites and the recent development of innovative molecular techniques (matrix CGH, RNA array chips, RQ-PCR, proteomics), we propose a global approach to investigate innovative treatment options of MCL and evaluate new predictive (pharmaco- genomics, minimal residual disease) and prognostic molecular markers (genomic alterations, RNA/proteome profiles) in such controlled studies. This translational approach of the European MCL Network will not only lead to more individualized therapeutic strategies...
Fields of science (EuroSciVoc)
- natural sciences biological sciences biochemistry biomolecules proteins proteomics
- medical and health sciences medical biotechnology cells technologies stem cells
- medical and health sciences basic medicine pathology
- natural sciences biological sciences genetics RNA
- medical and health sciences clinical medicine transplantation
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2002-LIFESCIHEALTH
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
MÜNCHEN
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.